Reported Earnings • May 18
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: ₹16.55 (up from ₹11.95 in FY 2025). Revenue: ₹11.8b (up 41% from FY 2025). Net income: ₹2.19b (up 39% from FY 2025). Profit margin: 19% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Duyuru • May 05
Aether Industries Limited to Report Q4, 2026 Results on May 15, 2026 Aether Industries Limited announced that they will report Q4, 2026 results on May 15, 2026 Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,161, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past three years. Price Target Changed • Feb 05
Price target increased by 10.0% to ₹1,154 Up from ₹1,049, the current price target is an average from 5 analysts. New target price is 13% above last closing price of ₹1,023. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₹17.58 for next year compared to ₹11.95 last year. Reported Earnings • Feb 04
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: ₹4.86 (up from ₹3.27 in 3Q 2025). Revenue: ₹3.17b (up 44% from 3Q 2025). Net income: ₹644.8m (up 49% from 3Q 2025). Profit margin: 20% (in line with 3Q 2025). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 21
Aether Industries Limited to Report Q3, 2026 Results on Feb 03, 2026 Aether Industries Limited announced that they will report Q3, 2026 results on Feb 03, 2026 Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹1,000, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past three years. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹893, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 2.1% over the past three years. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹4.07 (vs ₹2.63 in 2Q 2025) Second quarter 2026 results: EPS: ₹4.07 (up from ₹2.63 in 2Q 2025). Revenue: ₹2.84b (up 43% from 2Q 2025). Net income: ₹539.6m (up 55% from 2Q 2025). Profit margin: 19% (up from 18% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Oct 04
Aether Industries Limited to Report Q2, 2026 Results on Nov 13, 2025 Aether Industries Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Reported Earnings • Jul 25
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: ₹3.55 (up from ₹2.26 in 1Q 2025). Revenue: ₹2.59b (up 44% from 1Q 2025). Net income: ₹470.2m (up 57% from 1Q 2025). Profit margin: 18% (up from 17% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year. Duyuru • Jul 24
Aether Industries Limited, Annual General Meeting, Sep 12, 2025 Aether Industries Limited, Annual General Meeting, Sep 12, 2025. Duyuru • Jun 30
Aether Industries Limited to Report Q1, 2026 Results on Jul 24, 2025 Aether Industries Limited announced that they will report Q1, 2026 results on Jul 24, 2025 Duyuru • May 15
An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion. An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion on May 14, 2025. A cash consideration valued at INR 700 per share will be paid for 8.979173 million shares.
An undisclosed buyer completed the acquisition of 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai on May 14, 2025. New Risk • May 08
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • May 03
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: ₹11.95 (up from ₹6.31 in FY 2024). Revenue: ₹8.80b (up 47% from FY 2024). Net income: ₹1.58b (up 92% from FY 2024). Profit margin: 18% (up from 14% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Duyuru • Apr 26
Aether Industries Limited to Report Q4, 2025 Results on May 02, 2025 Aether Industries Limited announced that they will report Q4, 2025 results on May 02, 2025 Board Change • Apr 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 17
Aether Industries Limited Provides Revenue Guidance for the Financial Year 2024 Aether Industries Limited provided revenue guidance for the financial year 2024. The company anticipates net financial year to close to reach a revenue of INR 400 million. Duyuru • Jan 09
Aether Industries Limited Announces Revocation Order from GPCB for Resumption of Operations at Manufacturing Facility II Aether Industries Limited announced that the Gujarat Pollution Control Board (GPCB), through its communication received January 9, 2025, has revoked the closure order issued on November 29, 2023, following the fire incident, for Manufacturing Facility II. Consequently, the facility is now approved for 100% resumption of operations. The Company will commence full-capacity operations at Manufacturing Facility II upon ensuring compliance with the stipulated conditions. Duyuru • Jan 01
Aether Industries Limited to Report Q3, 2025 Results on Jan 17, 2025 Aether Industries Limited announced that they will report Q3, 2025 results on Jan 17, 2025 Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 19
Second quarter 2025 earnings released: EPS: ₹2.87 (vs ₹2.77 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.87 (up from ₹2.77 in 2Q 2024). Revenue: ₹2.09b (up 27% from 2Q 2024). Net income: ₹380.7m (up 3.8% from 2Q 2024). Profit margin: 18% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Duyuru • Oct 04
Aether Industries Limited to Report Q2, 2025 Results on Oct 18, 2024 Aether Industries Limited announced that they will report Q2, 2025 results on Oct 18, 2024 Duyuru • Jul 22
Aether Industries Limited, Annual General Meeting, Sep 10, 2024 Aether Industries Limited, Annual General Meeting, Sep 10, 2024. Reported Earnings • Jul 21
First quarter 2025 earnings released: EPS: ₹2.26 (vs ₹2.25 in 1Q 2024) First quarter 2025 results: EPS: ₹2.26 (up from ₹2.25 in 1Q 2024). Revenue: ₹1.80b (up 12% from 1Q 2024). Net income: ₹299.3m (flat on 1Q 2024). Profit margin: 17% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Duyuru • Jul 04
Aether Industries Limited to Report Q1, 2025 Results on Jul 19, 2024 Aether Industries Limited announced that they will report Q1, 2025 results on Jul 19, 2024 New Risk • Jun 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 20% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Reported Earnings • Feb 02
Third quarter 2024 earnings released: EPS: ₹1.32 (vs ₹2.81 in 3Q 2023) Third quarter 2024 results: EPS: ₹1.32 (down from ₹2.81 in 3Q 2023). Revenue: ₹1.67b (flat on 3Q 2023). Net income: ₹174.3m (down 50% from 3Q 2023). Profit margin: 11% (down from 21% in 3Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Duyuru • Jan 16
Aether Industries Limited to Report Q3, 2024 Results on Feb 01, 2024 Aether Industries Limited announced that they will report Q3, 2024 results on Feb 01, 2024 Reported Earnings • Nov 02
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: EPS: ₹2.77 (up from ₹2.19 in 2Q 2023). Revenue: ₹1.78b (up 27% from 2Q 2023). Net income: ₹366.8m (up 35% from 2Q 2023). Profit margin: 21% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Duyuru • Oct 20
Aether Industries Limited to Report Q2, 2024 Results on Oct 31, 2023 Aether Industries Limited announced that they will report Q2, 2024 results on Oct 31, 2023 Reported Earnings • Jul 27
First quarter 2024 earnings released: EPS: ₹2.25 (vs ₹2.46 in 1Q 2023) First quarter 2024 results: EPS: ₹2.25 (down from ₹2.46 in 1Q 2023). Revenue: ₹1.61b (flat on 1Q 2023). Net income: ₹298.1m (down 2.6% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Duyuru • Jul 12
Aether Industries Limited to Report Q1, 2024 Results on Jul 26, 2023 Aether Industries Limited announced that they will report Q1, 2024 results on Jul 26, 2023 New Risk • Jun 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Duyuru • Jun 24
Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion. Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 8,012,820
Price\Range: INR 936
Transaction Features: Regulation S; Subsequent Direct Listing Reported Earnings • May 08
Full year 2023 earnings released: EPS: ₹10.47 (vs ₹9.67 in FY 2022) Full year 2023 results: EPS: ₹10.47 (up from ₹9.67 in FY 2022). Revenue: ₹6.68b (up 13% from FY 2022). Net income: ₹1.30b (up 20% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Duyuru • May 07
Aether Industries Limited, Annual General Meeting, Jun 16, 2023 Aether Industries Limited, Annual General Meeting, Jun 16, 2023. Reported Earnings • Jan 22
Third quarter 2023 earnings released: EPS: ₹2.81 (vs ₹2.28 in 3Q 2022) Third quarter 2023 results: EPS: ₹2.81 (up from ₹2.28 in 3Q 2022). Revenue: ₹1.67b (up 10% from 3Q 2022). Net income: ₹350.4m (up 38% from 3Q 2022). Profit margin: 21% (up from 17% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Duyuru • Jan 21
Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat. Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat on January 20, 2023. The transaction will be funded by internal accruals and funding from banks.
Aether Industries Limited (NSEI:AETHER) Completed the acquisition of Industrial premises in Gujarat on January 20, 2023. Duyuru • Jan 02
Aether Industries Limited to Report Q3, 2023 Results on Jan 20, 2023 Aether Industries Limited announced that they will report Q3, 2023 results on Jan 20, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹2.27 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.40b (flat on 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 18% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹24.93 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.47b (up 1.5% from 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 17% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Duyuru • Nov 05
Aether Industries Limited to Report Q2, 2023 Results on Nov 11, 2022 Aether Industries Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Jul 27
First quarter 2023 earnings released: EPS: ₹2.46 (vs ₹3.34 in 1Q 2022) First quarter 2023 results: EPS: ₹2.46 (down from ₹3.34 in 1Q 2022). Revenue: ₹1.63b (up 8.3% from 1Q 2022). Net income: ₹306.2m (down 5.3% from 1Q 2022). Profit margin: 19% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Duyuru • Jul 26
Aether Industries Limited, Annual General Meeting, Sep 27, 2022 Aether Industries Limited, Annual General Meeting, Sep 27, 2022. Duyuru • Jul 19
Aether Industries Limited to Report Q1, 2023 Results on Jul 25, 2022 Aether Industries Limited announced that they will report Q1, 2023 results on Jul 25, 2022 Duyuru • Jun 17
Aether Industries Limited Approves Committee Changes The board of Aether Industries Limited in their Meeting held on 16th June, 2022, approved the resignation of Ms. Purnima Ashwin Desai and appointment of Mr. Jitendra Popatlal Vakharia as the audit committee member. Reported Earnings • Jun 17
Third quarter 2022 earnings released Third quarter 2022 results: EPS: ₹2.28. Revenue: ₹1.51b (flat on 3Q 2021). Net income: ₹254.0m (up ₹254.0m from 3Q 2021). Profit margin: 17% (up from null in 3Q 2021). Duyuru • Jun 09
Aether Industries Limited to Report Q4, 2022 Results on Jun 16, 2022 Aether Industries Limited announced that they will report Q4, 2022 results on Jun 16, 2022